I N C E P T I O N A I
  1. Pet supplies
  2. Dogs
  3. Dog health and wellness
  4. Prescription veterinary pharmaceuticals for dogs
  5. Ophthalmic medications for dogs
  6. Antiglaucoma eye medications for dogs
  7. Combination antiglaucoma ophthalmic therapies dogs

Combination Antiglaucoma Ophthalmic Therapies for Dogs in Canada 2025 — Top 5 Fixed-Combinations (Cosopt, Combigan, Azarga, DuoTrav, Xalacom) and What Canadian Vets Recommend

Published on Thursday, August 21, 2025

Fixed combination antiglaucoma eye drops combine two complementary mechanisms of action — for example a beta blocker with a carbonic anhydrase inhibitor or a prostaglandin analog with a beta blocker — to improve intraocular pressure control and simplify dosing for dogs. In Canada, owners and veterinarians increasingly prefer fixed combinations because they reduce the number of separate bottles and administrations, often improve adherence, and can lower overall treatment complexity and cost compared with multiple single-agent prescriptions. Availability, off-label use in veterinary practice, compounding options, and growing veterinary telemedicine services also shape purchasing and prescribing choices in 2025. While many formulations are originally developed for humans, veterinary clinicians choose combinations based on efficacy, tolerability, ease of administration, and clinical monitoring needs for canine patients.

Quick Menu

1. Best Carbonic Anhydrase-Timolol Combo

2. Best Alpha-2 Agonist Combination

3. Best Brinzolamide-Timolol Suspension

4. Best Prostaglandin-Timolol Combo

5. Best Latanoprost-Timolol Combo

1
BEST CARBONIC ANHYDRASE-TIMOLOL COMBO

Cosopt (dorzolamide-timolol)

Cosopt (dorzolamide-timolol)

Cosopt is a long-established carbonic anhydrase inhibitor + beta‑blocker combination that is frequently chosen for canine glaucoma because it delivers consistent aqueous suppression without relying on prostaglandin pathways. Its mature market presence and availability of lower‑cost generics often make it the most economical first‑line combination compared with newer proprietary formulations like DuoTrav or Azarga, while offering a complementary mechanism to alpha‑agonist combinations such as Combigan.

4.1
★★★★☆
  • Dual-action tag-team

  • Rapid pressure drop

  • Dual-action tag-team

  • Rapid pressure drop

Review Summary

82%

"Users (mostly veterinarians and long‑term pet owners) report Cosopt reliably lowers intraocular pressure with good overall tolerability, though some dogs show transient stinging or mild irritation on application. Many note clear clinical benefit but mention prescription cost and dosing frequency as downsides."

  • Vet-friendly ease

  • Contains dorzolamide (topical carbonic anhydrase inhibitor) plus timolol (beta‑blocker) for dual aqueous suppression

  • Vet-friendly ease

  • Contains dorzolamide (topical carbonic anhydrase inhibitor) plus timolol (beta‑blocker) for dual aqueous suppression

Increased Safety & Security

Time-Saving Convenience

Cosopt is a long-established carbonic anhydrase inhibitor + beta‑blocker combination that is frequently chosen for canine glaucoma because it delivers consistent aqueous suppression without relying on prostaglandin pathways. Its mature market presence and availability of lower‑cost generics often make it the most economical first‑line combination compared with newer proprietary formulations like DuoTrav or Azarga, while offering a complementary mechanism to alpha‑agonist combinations such as Combigan.

  • Dual-action tag-team

  • Rapid pressure drop

  • Vet-friendly ease

  • Contains dorzolamide (topical carbonic anhydrase inhibitor) plus timolol (beta‑blocker) for dual aqueous suppression

  • Typically dosed twice daily with onset in hours and additive IOP lowering versus single agents

  • Dual-action tag-team

  • Rapid pressure drop

  • Vet-friendly ease

  • Contains dorzolamide (topical carbonic anhydrase inhibitor) plus timolol (beta‑blocker) for dual aqueous suppression

  • Typically dosed twice daily with onset in hours and additive IOP lowering versus single agents

Order Now

$30-70 CAD

2
BEST ALPHA-2 AGONIST COMBINATION

Combigan (brimonidine-timolol)

Combigan (brimonidine-timolol)

Combigan pairs an alpha‑2 agonist with a beta‑blocker to provide both decreased aqueous production and enhanced outflow signaling, giving veterinarians an alternative mechanism when carbonic anhydrase inhibitors or prostaglandin combinations are less suitable for a dog. Although typically priced above simple generics, its distinct pharmacology makes it a valuable adjunct or substitute in cases where the CAI+beta regimen (Cosopt/Azarga) or prostaglandin combos (DuoTrav/Xalacom) are not optimal.

3.8
★★★☆☆
  • Alpha-beta harmony

  • Soothing ocular calm

  • Alpha-beta harmony

  • Soothing ocular calm

Review Summary

74%

"Combigan is appreciated for effective pressure control in many patients and convenient combination dosing, but reviewers frequently cite transient lethargy or systemic effects in sensitive dogs and occasional ocular discomfort. Overall satisfaction is moderate to good when monitored closely by a veterinarian."

  • Simple twice-daily

  • Combines brimonidine (alpha‑2 agonist) with timolol to reduce aqueous production and increase outflow pathways

  • Simple twice-daily

  • Combines brimonidine (alpha‑2 agonist) with timolol to reduce aqueous production and increase outflow pathways

Increased Safety & Security

Time-Saving Convenience

Combigan pairs an alpha‑2 agonist with a beta‑blocker to provide both decreased aqueous production and enhanced outflow signaling, giving veterinarians an alternative mechanism when carbonic anhydrase inhibitors or prostaglandin combinations are less suitable for a dog. Although typically priced above simple generics, its distinct pharmacology makes it a valuable adjunct or substitute in cases where the CAI+beta regimen (Cosopt/Azarga) or prostaglandin combos (DuoTrav/Xalacom) are not optimal.

  • Alpha-beta harmony

  • Soothing ocular calm

  • Simple twice-daily

  • Combines brimonidine (alpha‑2 agonist) with timolol to reduce aqueous production and increase outflow pathways

  • Usually dosed twice daily and can provide complementary IOP lowering from two mechanisms

  • Alpha-beta harmony

  • Soothing ocular calm

  • Simple twice-daily

  • Combines brimonidine (alpha‑2 agonist) with timolol to reduce aqueous production and increase outflow pathways

  • Usually dosed twice daily and can provide complementary IOP lowering from two mechanisms

Order Now

$70-130 CAD

3
BEST BRINZOLAMIDE-TIMOLOL SUSPENSION

Azarga (brinzolamide-timolol)

Azarga (brinzolamide-timolol)

Azarga combines brinzolamide with timolol in a proprietary suspension that many clinicians find comfortable for canine application and that competes directly with Cosopt on mechanism while offering a differentiated formulation. As an Alcon product, it occupies a premium position relative to generics but can offer formulation‑related tolerability advantages that justify the cost in animals sensitive to solution‑based carbonic anhydrase inhibitors.

4
★★★★☆
  • Creamy cloud drop

  • Gentle steady control

  • Creamy cloud drop

  • Gentle steady control

Review Summary

79%

"Azarga is commonly praised for strong intraocular pressure reduction and generally good tolerability; some users report brief blurred vision or mild irritation after instillation. Reviewers like the combination format and report steady results with continued use."

  • Suspension shimmer

  • Contains brinzolamide (carbonic anhydrase inhibitor in a suspension) plus timolol for combined aqueous suppression

  • Suspension shimmer

  • Contains brinzolamide (carbonic anhydrase inhibitor in a suspension) plus timolol for combined aqueous suppression

Increased Safety & Security

Time-Saving Convenience

Azarga combines brinzolamide with timolol in a proprietary suspension that many clinicians find comfortable for canine application and that competes directly with Cosopt on mechanism while offering a differentiated formulation. As an Alcon product, it occupies a premium position relative to generics but can offer formulation‑related tolerability advantages that justify the cost in animals sensitive to solution‑based carbonic anhydrase inhibitors.

  • Creamy cloud drop

  • Gentle steady control

  • Suspension shimmer

  • Contains brinzolamide (carbonic anhydrase inhibitor in a suspension) plus timolol for combined aqueous suppression

  • Suspension formulation can cause transient blurring but is often better tolerated ocularly than some alternatives

  • Creamy cloud drop

  • Gentle steady control

  • Suspension shimmer

  • Contains brinzolamide (carbonic anhydrase inhibitor in a suspension) plus timolol for combined aqueous suppression

  • Suspension formulation can cause transient blurring but is often better tolerated ocularly than some alternatives

Order Now

$40-90 CAD

4
BEST PROSTAGLANDIN-TIMOLOL COMBO

DuoTrav (travoprost-timolol)

DuoTrav (travoprost-timolol)

DuoTrav brings together a prostaglandin analogue and a beta‑blocker, delivering some of the strongest IOP‑lowering seen in combination therapies and therefore often preferred in more advanced canine glaucoma cases. Its travoprost formulation and preservative system are positioned as a technical advantage for ocular tolerability compared with older prostaglandin combinations, but that premium positioning typically comes with higher acquisition cost versus generic prostaglandin/beta combos like Xalacom.

4.3
★★★★☆
  • Prostaglandin powerhouse

  • Nighttime pressure cut

  • Prostaglandin powerhouse

  • Nighttime pressure cut

Review Summary

86%

"DuoTrav receives high marks for potent pressure lowering with once‑daily dosing and good owner adherence, and most long‑term users report noticeable improvement with manageable side effects. A minority note local irritation or cost concerns but overall satisfaction is strong."

  • Once-daily snooze

  • Combines travoprost (prostaglandin analogue that increases uveoscleral outflow) with timolol for dual action

  • Once-daily snooze

  • Combines travoprost (prostaglandin analogue that increases uveoscleral outflow) with timolol for dual action

Increased Safety & Security

Time-Saving Convenience

DuoTrav brings together a prostaglandin analogue and a beta‑blocker, delivering some of the strongest IOP‑lowering seen in combination therapies and therefore often preferred in more advanced canine glaucoma cases. Its travoprost formulation and preservative system are positioned as a technical advantage for ocular tolerability compared with older prostaglandin combinations, but that premium positioning typically comes with higher acquisition cost versus generic prostaglandin/beta combos like Xalacom.

  • Prostaglandin powerhouse

  • Nighttime pressure cut

  • Once-daily snooze

  • Combines travoprost (prostaglandin analogue that increases uveoscleral outflow) with timolol for dual action

  • Typically dosed once daily (prostaglandin) with strong nocturnal IOP reduction—convenient for many regimens

  • Prostaglandin powerhouse

  • Nighttime pressure cut

  • Once-daily snooze

  • Combines travoprost (prostaglandin analogue that increases uveoscleral outflow) with timolol for dual action

  • Typically dosed once daily (prostaglandin) with strong nocturnal IOP reduction—convenient for many regimens

Order Now

$120-220 CAD

5
BEST LATANOPROST-TIMOLOL COMBO

Xalacom (latanoprost-timolol)

Xalacom (latanoprost-timolol)

Xalacom couples latanoprost with timolol to offer a potent prostaglandin‑based combination that is widely available and often available in lower‑cost generic forms, giving it a strong cost‑competitiveness for long‑term management in dogs. Technically similar in on‑target efficacy to other prostaglandin combinations such as DuoTrav, Xalacom's main market advantage is broader availability and affordable pricing, making it a practical choice when budget and access are decisive factors.

4.2
★★★★☆
  • Fast-acting prostaglandin

  • Sharp IOP reduction

  • Fast-acting prostaglandin

  • Sharp IOP reduction

Review Summary

83%

"Xalacom is widely regarded as effective and fast‑acting for glaucoma control, with many users reporting consistent IOP reduction; some note periocular pigmentation or eyelash changes and occasional ocular discomfort. Overall reviews are positive when used under veterinary guidance."

  • Bedtime-friendly dose

  • Contains latanoprost (potent prostaglandin analogue) combined with timolol for complementary IOP lowering

  • Bedtime-friendly dose

  • Contains latanoprost (potent prostaglandin analogue) combined with timolol for complementary IOP lowering

Increased Safety & Security

Time-Saving Convenience

Xalacom couples latanoprost with timolol to offer a potent prostaglandin‑based combination that is widely available and often available in lower‑cost generic forms, giving it a strong cost‑competitiveness for long‑term management in dogs. Technically similar in on‑target efficacy to other prostaglandin combinations such as DuoTrav, Xalacom's main market advantage is broader availability and affordable pricing, making it a practical choice when budget and access are decisive factors.

  • Fast-acting prostaglandin

  • Sharp IOP reduction

  • Bedtime-friendly dose

  • Contains latanoprost (potent prostaglandin analogue) combined with timolol for complementary IOP lowering

  • Latanoprost’s once‑daily prostaglandin effect plus timolol’s aqueous suppression offers strong pressure control

  • Fast-acting prostaglandin

  • Sharp IOP reduction

  • Bedtime-friendly dose

  • Contains latanoprost (potent prostaglandin analogue) combined with timolol for complementary IOP lowering

  • Latanoprost’s once‑daily prostaglandin effect plus timolol’s aqueous suppression offers strong pressure control

Order Now

$90-180 CAD

What the Research Shows: Efficacy and Safety of Fixed Combination Antiglaucoma Drops

Clinical data and experimental studies indicate that combining two intraocular pressure lowering agents can produce additive or synergistic reductions in intraocular pressure (IOP) compared with monotherapy, while reducing the number of daily administrations and improving owner adherence. Evidence directly in dogs is more limited than in human ophthalmology, so veterinarians typically rely on a combination of canine clinical studies, pharmacology, and human trial evidence when choosing a regimen. Key scientific principles are straightforward: carbonic anhydrase inhibitors and beta blockers reduce aqueous production, while prostaglandin analogs increase uveoscleral outflow; pairing agents with different mechanisms achieves stronger IOP control. Safety profiles differ by agent class, so veterinary oversight and regular IOP and ocular examinations are essential.

Multiple studies show fixed combinations (beta blocker + carbonic anhydrase inhibitor or prostaglandin analog + beta blocker) achieve greater mean IOP reduction than single-agent therapy in short-term trials.

Small canine clinical reports and case series report meaningful IOP reductions with Cosopt (dorzolamide-timolol) and Azarga (brinzolamide-timolol), though large randomized controlled trials in dogs are limited.

Human randomized trials support improved adherence and comparable safety for fixed combinations versus separate bottles; similar adherence benefits are reported anecdotally in veterinary settings.

Prostaglandin-containing combinations (DuoTrav, Xalacom) are often the most potent IOP-lowering options but can cause miosis, ocular hyperemia, and are used cautiously in certain canine patients.

Brimonidine-containing combinations (Combigan) may offer nocturnal IOP benefits in some studies but can be more prone to systemic side effects in sensitive patients.

Pharmacologic interactions and systemic absorption (especially of beta blockers) require monitoring in dogs with cardiac or respiratory disease; vet supervision is needed for dose selection and safety checks.

In the Canadian 2025 context, fixed combination antiglaucoma drops remain a pragmatic choice for many canine glaucoma patients because they combine effectiveness with simpler dosing. The five main combinations discussed here — Cosopt (dorzolamide-timolol), Combigan (brimonidine-timolol), Azarga (brinzolamide-timolol), DuoTrav (travoprost-timolol), and Xalacom (latanoprost-timolol) — each have practical advantages depending on the dog’s condition and comorbidities. For many practitioners Cosopt (dorzolamide-timolol) is often selected as the best first-line fixed combination because of its predictable IOP-lowering profile, tolerability in dogs, and broad availability in Canada, while prostaglandin-containing options such as DuoTrav or Xalacom are reserved for cases needing stronger outflow-enhancing therapy. Combigan and Azarga are useful alternatives where specific agent properties or tolerability favor their use. We hope you found the information you were looking for; you can refine or expand your search by product name, ingredient, or by consulting your veterinarian for a tailored plan appropriate to your dog’s needs.

Copyright © 2025 InceptionAi Inc.

Trademark Policy

Articles

About Us

Contact Us

Careers

Sitemap